Enhanced Kidney Follow-up for AKI Survivors in Care Transitions
Enhanced Kidney Follow-up for AKI Survivors in Care Transitions (The ACT Study): Impact on Patient Reported Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- KDIGO Stage 3 AKI
- Primary care provider at Mayo Rochester.
Exclusion Criteria:
- Patient with need for dialysis at discharge from hospital or hospice.
- Enrolled in the Primary Care Transition Program.
- Non-English speaking.
- Cognitive impairment.
- Dementia.
- Mini-Cog score of less than 3.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Usual care
|
|
|
Active Comparator: Education alone
|
Kidney health education will be delivered prior to discharge by trained nurse educators.
|
|
Active Comparator: Education and follow-up
|
In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Kidney Knowledge Survey (mKIKS)
Time Frame: 14-days after last study contact
|
Assesses participants' objective knowledge about AKI causes, risk factors, and management.
The minimum score is 0, maximum score is 15, higher scores indicate greater knowledge.
|
14-days after last study contact
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief health literacy screen
Time Frame: 30-days post hospitalization
|
A 4-item tool to assess health literacy.
Minimum score of 0, maximum score 20, higher scores indicate higher health literacy
|
30-days post hospitalization
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10
Time Frame: 30-days post hospitalization
|
Based on the provided responses, an overall summary score, and two subset scores - Global health physical and Global health mental can be calculated.
Raw summed score are converted into T-scores.
Higher scores indicate better health.
|
30-days post hospitalization
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erin F Barreto, PharmD, RPh, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-004204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.